RxDoctor Payments Data

John Brown, DO

Family Medicine · Little Rock, ARNPI 1720146509

Payments from drug & device makers

$2,491in general payments, 2019–2025

Across 72 payments — averaging $34.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$554
  • Lilly USA, LLC$340
  • Pfizer$319
  • AstraZeneca$297
  • AbbVie$233
  • Nalu Medical, Inc.$187
  • plus $561 from 11 others

What the payments were for

  • Travel & lodging$1877%
  • Food & beverage$2,30493%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,491 in reported general payments places this provider in the 75th percentile of 1,347 family medicine providers in Arkansas.

See all family medicine providers in Arkansas

Medicare billing

Part B allowed, 2024
$243,311
Medicare patients
250
Services billed
2,857

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen2,764$88,223
Meperidine Hcl13$46,231
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen1,147$41,212
BelbucaBuprenorphine Hcl17$16,040
Gabapentin792$8,621
LinzessLinaclotide16$8,516
Oxycodone Hcl515$7,676
Lidocaine62$6,889
Pregabalin308$5,541
Morphine Sulfate ErMorphine Sulfate223$4,746
Tizanidine Hcl586$4,361
Cyclobenzaprine Hcl464$4,352
Buprenorphine11$3,593
Fentanyl44$3,093
Diclofenac Sodium75$2,126

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$233$8,51616 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,347 family medicine providers in Arkansas.

Other family medicine in Little Rock

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →